Milliplex human cytokine chemokine growth factor panel a kit hcyta 60k px48

The following 48 analytes were measured at a protein level by multiplex xMAP technology using the MILLIPLEX Human Cytokine/Chemokine/Growth Factor Panel A kit (HCYTA-60K-PX48, Merck, Darmstadt, Germany): sCD40L, EGF, Eotaxin-1/CCL11, FGF-2/FGF-basic, Flt-3 ligand, Fractalkine/CX3CL1, G-CSF, GM-CSF, GROα, IFNα2, IFN-γ, IL-1α, IL-1β, IL-1RA, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8/CXCL8, IL-9, IL-10, IL-12(p40), IL-12(p70), IL-13, IL-15, IL-17A/CTLA8, IL-17E/IL-25, IL-17F, IL-18, IL-22, IL-27, IP-10/CXCL10, MCP-1/CCL2, MCP-3/CCL7, M-CSF, MDC/CCL22, MIG/CXCL9, MIP-1α/CCL3, MIP-1β/CCL4, PDGF-AA, PDGF-AB/BB, RANTES/CCL5, TGF-α, TNF-α, TNF-β, and VEGF-A. Multiplex-based assay read-out was performed using MAGPIX system (Merck) with the xPONENT 4.2 software (Merck) in accordance with the manufacturer’s instruction with overnight incubation of the samples with primary antibodies. Final analysis was carried out with the MILLIPLEX Analyst v5.1 software (Merck). Measurements were performed twice for each sample. Release of the analytes in control and experimental samples was compared with unpaired two-sample t-test using GraphPad Prism v.8.0.1 (GraphPad Software, Inc, San Diego, CA, USA). The p values ≤ 0.05 were considered significant.

The following 48 analytes were measured at a protein level by multiplex xMAP technology using the MILLIPLEX Human Cytokine/Chemokine/Growth Factor Panel A kit (HCYTA-60K-PX48, Merck, Darmstadt, Germany): sCD40L, EGF, Eotaxin-1/CCL11, FGF-2/FGF-basic, Flt-3 ligand, Fractalkine/CX3CL1, G-CSF, GM-CSF, GROα/CXCL1, IFNα2, IFNγ, IL-1α, IL-1β, IL-1RA, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8/CXCL8, IL-9, IL-10, IL-12(p40), IL-12(p70), IL-13, IL-15, IL-17A/CTLA8, IL-17E/IL-25, IL-17F, IL-18, IL-22, IL-27, IP-10/CXCL10, MCP-1/CCL2, MCP-3/CCL7, M-CSF, MDC/CCL22, MIG/CXCL9, MIP-1α/CCL3, MIP-1β/CCL4, PDGF-AA, PDGF-AB/BB, RANTES/CCL5, TGFα, TNFα, TNFβ, and VEGF-A. Multiplex-based assay read-out was performed using the MAGPIX system (Merck) with the xPONENT 4.2 software (Merck) in accordance with the manufacturer’s instruction with overnight incubation of the samples with primary antibodies. A final analysis was carried out with the MILLIPLEX Analyst v5.1 software (Merck). Measurements were performed twice for each sample. Release of the analytes in control and experimental samples was compared with an unpaired two-sample t-test using GraphPad Prism v.8.0.1 (GraphPad Software, Inc., San Diego, CA, USA). The p values ≤ 0.05 were considered significant.